Further, Shoemaker et al. found that ABT-263, another BCL-2 inhibitor, caused tumor regression in SCLC xenografts, further highlighting the potential therapeutic application of this inhibitor family in clinical practice [122]. The gene discussed is BCL2; the disease is small cell lung carcinoma.